|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The drug delivery devices market was valued at USD 258.81 billion in 2021, and it is expected to reach USD 394.03 billion by 2027, registering a CAGR of 7.40% during the forecast period of 2022-2027.
With the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments were/are working toward offering efficient medical treatment to COVID-19 patients, and drug delivery devices are expected to play a vital role in this context. For example, large-scale vaccination programs are being undertaken all over the world to immunize people against the SARS-CoV-2 virus but still, many companies are working on more efficient ways of delivering COVID-19 therapeutics to patients and investing heavily in it which is expected to have a significant impact on the drug delivery market. For instance, in February 2022, Glenmark Pharmaceuticals Limited launched a nitric oxide nasal spray called FabiSpray in India for the treatment of adult patients with COVID-19 having a high risk of progression of the disease. Hence, COVID-19 is expected to have a significant impact on the growth of the drug delivery market over the forecast period.
The rising prevalence of chronic diseases, technological advancements, and the growth in the biologics market are significant factors expected to drive the development of the drug delivery devices market over the forecast period. As drug delivery devices help deliver the drugs, which are beneficial for the targeted population to recover faster, there has been a growing adoption and inclination toward advanced drug delivery devices. Moreover, a rising number of cancers, respiratory diseases, and diabetic patients worldwide may promote the adoption of drug delivery devices and drive the overall market. According to the data published by the International Agency for Research on Cancer 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die. Breast, colorectal, lung, cervical, and thyroid cancers are common among women. In contrast, lung and prostate cancer is the most common among men, accounting for nearly one-third of all male cancers. This growing burden of cancer increases the adoption of drug delivery devices, which will contribute significantly to the market growth over the studied forecast period.
Additionally, the article entitled “Drug Delivery System in the Treatment of Diabetes Mellitus” in July 2020 mentioned that it is necessary to develop appropriate delivery systems and complete therapy strategies according to the nature of drugs and diabetes mellitus. As per the source, drug delivery devices have been potentially beneficial in many aspects of diabetes treatment, effects such as improving the stability of drugs, overcoming different biological barriers in vivo to increase bioavailability, and acting as an intelligent automatized system to mimic endogenous insulin delivery and reduce the risk of hypoglycemia. These benefits of the devices for the treatment of diabetes is Increasing demand for novel drug delivery devices and are expected to boost the growth of the studied market.
The technological advancements in drug delivery devices are ongoing to make them more patient-friendly, accessible, and accurate. In line with this, players invest more in research and development and continuously innovate new technologies and advanced drug delivery devices. In May 2021, Phillips-Medisize launched its Aria Smart Autoinjector platform and unlocked innovation, differentiation, and sustainability in the digital drug-delivery device market. This device is featured advanced technologies such as a modular drug delivery platform that supports a variety of drug formulations and viscosities that have built-in Bluetooth, which enables connectivity to smartphones, tablets, and mobile apps. In addition, Roche has developed a Port Delivery System with ranibizumab (PDS), a drug delivery implant to free patients with wet age-related macular degeneration from the need to undergo frequent eye injections in June 2021. Food and drug administration approved this PDS drug delivery implant for priority review. This active involvement of the major players is anticipated to have a considerable impact on the growth of the studied market. Thus, all aforementioned factors are expected to boost the market growth over the forecast period. However, the risk of needlestick injury may restrain market growth over the forecast period.
Scope of the Report
As per the scope, drug delivery devices or systems are the tools used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances into the body. The drug delivery devices market is segmented by route of administration (injectable, topical, ocular, and others), application (cancer, cardiovascular, diabetes, infectious diseases, and other applications), end user (hospitals, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.
|By Route of Administration|
|Other Route of Administration|
|By End User|
|Ambulatory Surgical Centers|
|Other End Users|
Key Market Trends
By Route of Administration, the Topical Drug Delivery Devices Segment is Estimated to Witness a Healthy Growth Over the Forecast Period
Topical drug delivery involves drug transport from a product on the skin to a local target site and then clearance by diffusion, metabolism, and dermal circulation to the rest of the body and deeper tissues.
The major factors fueling the growth of the segment are the increasing implementation of strategic initiatives and the development of novel products. For instance, as of March 2021, scientists at Stanford University and the University of North Carolina at Chapel Hill (UNC) produced a 3D-printed vaccine patch that they claim provides more excellent protection than a typical vaccine shot. The development of such novel products is fueling the usage of drug delivery products, thereby contributing to market growth.
Several market players are engaged in implementing strategic initiatives, thereby contributing to the market growth. For instance, in December 2020, Agile Therapeutics, Inc., a women’s healthcare company, commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. Moreover, in June 2020, Vektor Pharma introduced a generic version of the Neupro patch (rotigotine), a transdermal patch that indicated against the symptoms of Parkinson’s disease.
Thus, due to the above-mentioned factors, the topical route of the administration segment is expected to grow significantly during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Hold a Significant Share in the Drug Delivery Market Over Forecast Period
The United States (US) drug delivery devices market is estimated to grow significantly during the study period owing to rising incidences of chronic diseases like cancer and HIV, among others, increasing product launches, and rising initiatives by key market players. For instance, according to the American Cancer Society’s 2022 report, approximately 1.9 million new cancer cases are expected to be diagnosed in 2022 in the United States and cancer cases are further expected to increase in the country which is expected to increase the demand for the drug delivery devices for various therapeutics as demand for cancer treatment is quite high in the region owing to the high mortality rate associated with the disease, which is expected to boost growth in the drug delivery market.
The launch of new products in the country will also help drive market growth. For instance, in February 2022, the United States Food and Drug Administration approved the generic Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility off episodes associated with advanced Parkinson’s disease. In January 2021, Novartis AG invested in Credence MedSystems to support the development and scale-up of its drug delivery systems. This initiative facilitates Novartis AG to employ the Credence technology in its injectable medicines. Similarly, in November 2020, Croda International PLC entered an agreement with Pfizer Inc. to supply innovative drug delivery systems for Pfizer’s COVID-19 Vaccine Candidate.
Furthermore, In March 2022, Corium received United States Food and Drug Administration approval for Adlarity to treat patients with mild, moderate, or severe dementia associated with Alzheimer’s. The launch of transdermal patches in the country is expected to boost the studied market during the study period. Moreover, strategic initiatives by market players such as partnerships and collaborations for increasing the production of drug delivery devices will lead to lucrative market growth. For instance, in May 2020, the Department of Defense and the United States Department of Health and Human Services gave a contract of USD 138 million to ApiJect Systems America for “Project Jumpstart” and “The RAPID USA,” which will work together to expand United States production capability of medical-grade injection devices. This project aided in manufacturing more than 100 million prefilled syringes for distribution across the country, thereby driving the market. Therefore, the rising number of chronic diseases and product launches in the country are expected to grow with a healthy CAGR over the forecasted period.
To understand geography trends, Download Sample Report
The drug delivery devices market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Pfizer Inc., Novartis AG, Becton, Dickinson and Company, Holozymes Inc. (Antares Pharma Inc.), Elcam Medical, and Biocorp, among others. The major players have focused on strategic alliances, such as acquisitions, collaborations, investment in R&D activities, and launching new products to secure their position in a competitive global market.
Becton, Dickinson and Company
West Pharmaceutical Services Inc.
Holozymes Inc. (Antares Pharma Inc.)
- In February 2022, Takeda received United States Food and Drug Administration (FDA) approval for TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
- In February 2022, Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd., reported that its UniSafe 1mL safety device for prefilled syringes had been approved as a combination product in Asia.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Technological Advancements
4.2.3 Growth in the Biologics Market
4.3 Market Restraints
4.3.1 Risk of Needlestick Injuries
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Route of Administration
5.1.4 Other Route of Administration
5.2 By Application
5.2.4 Infectious diseases
5.2.5 Other Applications
5.3 By End User
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 F Hoffmann-La Roche Ltd
6.1.4 Johnson and Johnson
6.1.5 Bayer AG
6.1.6 Becton, Dickinson and Company
6.1.8 Holozymes Inc. (Antares Pharma Inc.)
6.1.9 GlaxoSmithKline PLC
6.1.10 Teva Pharmaceutical Industries Ltd
6.1.12 Merck KGaA
6.1.13 West Pharmaceutical Services Inc.
6.1.14 Molex (Philips Medisize)
6.1.15 Elcam Medical
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Drug Delivery Devices Market market is studied from 2019 - 2027.
What is the growth rate of Global Drug Delivery Devices Market?
The Global Drug Delivery Devices Market is growing at a CAGR of 7.4% over the next 5 years.
Which region has highest growth rate in Global Drug Delivery Devices Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Drug Delivery Devices Market?
North America holds highest share in 2021.
Who are the key players in Global Drug Delivery Devices Market?
Biocorp, Becton, Dickinson and Company, West Pharmaceutical Services Inc., Elcam Medical , Holozymes Inc. (Antares Pharma Inc.) are the major companies operating in Global Drug Delivery Devices Market.